VTAMA

Peak

tapinarof

NDATOPICALCREAM
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4

Mechanism of Action

Aryl Hydrocarbon Receptor Agonists

Pharmacologic Class:

Aryl Hydrocarbon Receptor Agonist

Clinical Trials (4)

NCT06742957Phase 3Completed

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Started Dec 2024
560 enrolled
Plaque Type Psorisis
NCT04053387Phase 3Completed

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Started Aug 2019
763 enrolled
Plaque Psoriasis
NCT03983980Phase 3Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Started Jun 2019
515 enrolled
Plaque Psoriasis
NCT03956355Phase 3Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Started May 2019
510 enrolled
Plaque Psoriasis

Loss of Exclusivity

LOE Date
Nov 13, 2039
166 months away
Patent Expiry
Nov 13, 2039
Exclusivity Expiry
Dec 12, 2027

Patent Records (5)

Patent #ExpiryTypeUse Code
11612573
May 19, 2036
U-2625
11622945
May 19, 2036
Product
10195160
May 19, 2036
Product
11458108
May 19, 2036
Product
10426743
May 19, 2036
U-2625